Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
DexCom Promotes Jake Leach to Chief Operating Officer
DexCom Promotes Jake Leach to Chief Operating Officer


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the promotion of Jake Leach to the role of chief operating

Simulations Plus Releases State-of-the-Art QSP Software for Interstitial Lung Disease
Simulations Plus Releases State-of-the-Art QSP Software for Interstitial Lung Disease


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS)

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
DGAP-News: Vita 34 records moderate upward trend in the second quarter
DGAP-News: Vita 34 records moderate upward trend in the second quarter
DGAP-News: Vita 34 records moderate upward trend in the second quarter
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
MD Medical Group Investments Plc: Results of the Extraordinary General Meeting of shareholders
MD Medical Group Investments Plc: Results of the Extraordinary General Meeting of shareholders
MD Medical Group Investments Plc: Results of the Extraordinary General Meeting of shareholders
DGAP-Adhoc: Vita 34 lowers sales and earnings guidance due to IFRS 15 effect and accelerated restructuring measures
DGAP-Adhoc: Vita 34 lowers sales and earnings guidance due to IFRS 15 effect and accelerated restructuring measures
DGAP-Adhoc: Vita 34 lowers sales and earnings guidance due to IFRS 15 effect and accelerated restructuring measures
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Sonova to enable fully immersive conversations in virtually any situation with new Lumity platform
Sonova to enable fully immersive conversations in virtually any situation with new Lumity platform
Sonova to enable fully immersive conversations in virtually any situation with new Lumity platform
Condor Technologies nimmt den Handel an der Börse Euronext in Paris wieder auf
Condor Technologies nimmt den Handel an der Börse Euronext in Paris wieder auf


Wir freuen uns, Ihnen die Wiederaufnahme des Handels von Condor Technologies (MLMFI.PA) am 23. August an der Euronext Access Exchange in Paris mitteilen zu dürfen.



Die Wiederaufnahme des Handels

Condor Technologies to Reopen Trading on the Euronext Exchange in Paris
Condor Technologies to Reopen Trading on the Euronext Exchange in Paris


We are pleased to announce the reopening of the trading sessions on August 23rd for Condor Technologies (MLMFI.PA) on the Euronext Access Exchange in Paris.



The resumption of the trading

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Sonova to accelerate expansion of direct consumer access in Chinese market with acquisition of leading network of clinics
Sonova to accelerate expansion of direct consumer access in Chinese market with acquisition of leading network of clinics
Sonova to accelerate expansion of direct consumer access in Chinese market with acquisition of leading network of clinics
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
QuidelOrtho Announces $300 Million Share Repurchase Authorization: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho Announces $300 Million Share Repurchase Authorization


QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
DGAP-News: M1 Kliniken AG announces financials for H1-2022: positive business development despite cooling of general consumer climate
DGAP-News: M1 Kliniken AG announces financials for H1-2022: positive business development despite cooling of general consumer climate
DGAP-News: M1 Kliniken AG announces financials for H1-2022: positive business development despite cooling of general consumer climate
Agilent Reports Third-Quarter Fiscal Year 2022 Financial Results
Agilent Reports Third-Quarter Fiscal Year 2022 Financial Results


Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.72 billion for the third quarter ended July 31, 2022, an increase of 8% compared to the third quarter of 2021 and up 13% on a core(1

Premier, Inc. Reports Fiscal-Year 2022 Fourth-Quarter and Full-Year Results
Premier, Inc. Reports Fiscal-Year 2022 Fourth-Quarter and Full-Year Results


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal-year 2022 fourth quarter and full year ended June 30, 2022

Sonova revises FY 2022/23 outlook due to subdued market 
and ongoing input cost challenge
Sonova revises FY 2022/23 outlook due to subdued market  and ongoing input cost challenge
Sonova revises FY 2022/23 outlook due to subdued market  and ongoing input cost challenge